Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio
October 12 2017 - 12:54PM
Business Wire
Roche and Ncardia have reached a broad licensing agreement
whereby Roche and its affiliate companies gain access to key
disease modeling patents from Ncardia.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171012006114/en/
Ncardia is a leader in standardized,
validated iPSC assays for safety, phenotypic screening and disease
modeling. For scientists conducting cardiovascular and neural
safety and efficacy projects, Ncardia is providing tools to
facilitate accelerated development of drugs, while replacing animal
studies and putting a "human" aspect back into drug discovery.
(Graphic: Business Wire)
Ncardia was recently formed through the merger of Axiogenesis
and Pluriomics. The two companies have pioneered the development of
stem cell derived cells for drug discovery and safety and in
particular have advanced disease and tissue modeling
applications.
The Ncardia patent portfolio consists of several granted patents
in Europe, the USA and Japan. The drug screening and disease
modeling technology not only involves patient iPSC cells, induction
of the disease phenotype can also be achieved through genetic
manipulation, mRNA or siRNA transfection or through chemical or
physical induction.
Dr Stefan Braam, CEO Ncardia, commented: “Ncardia mission is to
support and enable our clients to make better medicines faster. The
combination of iPSC derived disease models with phenotypic
screening is an extremely powerful method to identify new drug
candidates. This license marks a further step in Ncardia technology
strategy aimed at addressing the potential of stem cell
applications in the drug discovery and development market."
Roche has now obtained a non-exclusive, worldwide license to the
key Ncardia disease modeling patents claiming the use of stem cell
derived cells disease models for the discovery & development of
novel drug candidates. The financial terms of the agreements are
not disclosed.
“This license is the first step of our strategy to make our
technology available to the pharmaceutical drug discovery &
development market.” Felix von Haniel VP Sales and BD of Ncardia.
In addition to disease modeling applications Ncardia is committed
to providing the most predictive healthy human cellular models to
improve and accelerate safety testing.
Ncardia: Ncardia (www.ncardia.com) believes that stem cell
technology will help to get better medicines to patients faster.
The company develops, produces and commercializes highly predictive
human cellular assay systems for safety and efficacy testing. The
cardiac product portfolio encompasses a broad panel of hiPSC
derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U™) as
well cardiac fibroblasts (FibroCor.4U™). In addition, the company
delivers the Cardioplate™ product line of quality controlled
ready to use assay plates. The neural cell portfolio contains the
pan-neuronal product CNS.4U®, the peripheral neurons product
Peri.4U®, and astrocyte product Astro.4U®.
Ncardia is committed to deliver its clients working assays
solutions through in house assay development and extensive support.
The company has a wide range of supported applications and compound
assay services such as of electrophysiology, biochemistry and
contraction based assays for predictive safety pharmacology and
toxicology testing. In addition, Ncardia develops and provides its
customers with a broad portfolio of cardiovascular services from
disease modeling to cardiovascular drug efficacy screening.
Ncardia is based in Belgium, the Netherlands, Germany and in the
USA. The company is privately held and established following the
merger of Pluriomics and Axiogenesis.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171012006114/en/
Media:NcardiaFelix von Hanielfelix.haniel@ncardia.com